中国医药科学Issue(21)：55-57,3.
β2-受体激动剂联合吸入糖皮质激素治疗持续性哮喘的临床疗效分析
Clinical efficacy analysis of β2-agonist and inhaled corticosteroid in treatment of persistent asthma
李翠萍 1王石1
作者信息
- 1. 辽宁省兴城市人民医院血液净化中心，辽宁兴城 125100
- 折叠
摘要
Abstract
Objective To investigate clinical efficacy of β2-agonist and inhaled corticosteroid in treatment of persistent asthma. Methods 134 patients with persistent asthma were selected in hospital from October 2011 to October 2013,who were randomly divided into two groups.67 patients treated formoterol as control group.67 patients treated formoterol and budesonide as observation group. Disease control was evaluated by asthma control test score and asthma control questionnaire score. Treatment and adverse reactions were compared between two groups. Results After treatment, alleviate drug dosage significantly reduced while compliance rate of assessment; percentage of FEV1.0;percentage of PEF significantly improved in two groups. Alleviate drug dosage in observation group was significantly less than control group. Compliance rate of assessment; percentage of FEV1.0; percentage of PEF; asthma control test score in observation group were significantly higher than control group. Disease control in observation group were significantly better than control group. Asthma control questionnaire score; incidence of adverse reaction in observation group were significantly lower than control group. Difference was statistically significant (P < 0.05). Conclusion β2-agonist and inhaled corticosteroid have significant clinical efficacy in treatment of persistent asthma,which can significantly improve clinical symptoms.β2-agonist and inhaled corticosteroid have less adverse reaction and high safety, which are worthy of clinical use.关键词
β2- 受体激动剂/糖皮质激素/持续性哮喘Key words
β2-agonist/Corticosteroid/Persistent asthma分类
医药卫生引用本文复制引用
李翠萍,王石..β2-受体激动剂联合吸入糖皮质激素治疗持续性哮喘的临床疗效分析[J].中国医药科学,2014,(21):55-57,3.
